Slideflow Labs provides an AI platform that enables pathology labs and research teams to develop, validate, and deploy digital pathology biomarkers on local hardware with optional secure cloud scaling. The software includes end‑to‑end pipelines for training foundation models on whole‑slide images, uncertainty quantification, generative explainability, FHIR‑compatible APIs, and a library of pre‑validated biomarkers for rapid clinical translation.
Funding
Funding not disclosed
Founders
Product
Problem
Pathology laboratories and research teams often lack the computational expertise, infrastructure, and validated tools needed to develop and deploy AI-driven digital biomarkers for tasks such as molecular target identification, risk stratification, and treatment response prediction. Existing solutions are typically cloud‑only, expensive, or require extensive engineering effort, leading to slow adoption and limited reproducibility.
Solution
Slideflow Labs offers a unified AI platform that brings state‑of‑the‑art foundation models for digital pathology directly into the user’s environment. The software runs on inexpensive local hardware while synchronizing with a secure, cloud‑based backend for storage and compute scaling. Built on an open‑source foundation, the platform supports end‑to‑end model development, from data preprocessing and training to validation, uncertainty quantification, and production deployment. Generative AI modules generate visual explanations of learned histopathological features, helping users assess model bias and interpretability. A growing library of pre‑validated biomarkers accelerates research and enables rapid clinical translation without the need for extensive custom development.
Target Audience
Primary users are pathology departments, academic research labs, and biotech/pharma teams that need to develop, validate, and operationalize AI‑driven digital biomarkers for cancer diagnostics and therapeutic decision‑making.
Features
- Integrated pipeline for training, evaluating, and deploying deep‑learning models on whole‑slide images using the latest foundation models.
- Local, low‑cost hardware support combined with encrypted cloud synchronization for scalable compute and secure data handling.
- Patent‑pending uncertainty quantification that flags out‑of‑distribution inputs and enables abstention on unfamiliar cases.
- Generative AI explainability tools that synthesize histology visualizations to illustrate model decision pathways and reduce bias.
- Open‑source core with enterprise‑grade extensions, allowing seamless transition from research prototypes to production‑ready deployments.
- API and FHIR‑compatible interfaces for exporting biomarker predictions into laboratory information systems and electronic health records.
- Curated repository of published digital biomarkers (e.g., breast cancer recurrence risk, neuroblastoma molecular subtyping, thyroid BRAF‑RAS signatures) ready for immediate use or further customization.